Jonathan Phillips, Deepak Subedi, Steff C Lewis, Catriona Keerie, Owen Cronin, Mary Porteous, David Moore, Roseanne Cetnarskyj, Lakshminarayan Ranganath, Peter L Selby, Tolga Turgut, Geeta Hampson, Rama Chandra, Shu Ho, Jon Tobias, Steven Young-Min, Malachi J McKenna, Rachel K Crowley, William D Fraser, Jonathan C Y Tang, Luigi Gennari, Rannuccio Nuti, Maria Luisa Brandi, Javier Del Pino-Montes, Jean-Pierre Devogelaer, Anne Durnez, Giovanni Carlo Isaia, Marco Di Stefano, Nuria Guanabens, Josep Blanch Rubio, Markus J Seibel, John P Walsh, Sarah L Rea, Mark A Kotowicz, Geoffrey C Nicholson, Emma L Duncan, Gabor Major, Anne Horne, Nigel Gilchrist, Stuart H Ralston
INTRODUCTION: Paget's disease of bone (PDB) frequently presents at an advanced stage with irreversible skeletal damage. Clinical outcomes might be improved by earlier diagnosis and prophylactic treatment. METHODS: We randomised 222 individuals at increased risk of PDB because of pathogenic SQSTM1 variants to receive 5 mg zoledronic acid (ZA) or placebo. The primary outcome was new bone lesions assessed by radionuclide bone scan. Secondary outcomes included change in existing lesions, biochemical markers of bone turnover and skeletal events related to PDB...
December 20, 2023: Annals of the Rheumatic Diseases